ArticleThe plant genome2026
A high-recovery, high-density targeted genotyping platform for cranberry.
Article in The plant genome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeted population genomics uncovers demographic history and genetic divergence in north American wild cranberry.Horticulture research · 2026Article
- Genome Database for Vaccinium: a knowledgebase for genetics, genomics, and breeding research.Genetics · 2026Article
- A high-recovery, high-density targeted genotyping platform for cranberry.The plant genome · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
The American cranberry (Vaccinium macrocarpon) is a commercially important berry species native to North America. Cranberry is a popular fruit crop with many known health benefits. Thus far, genotyping-by-sequencing (GBS) was the only high-throughput genotyping technique available in cranberry. While GBS is cost efficient, it has the disadvantage of producing variant calls that cannot be easily transferred between populations and across studies. In this study, we report the development of the first targeted high-throughput genotyping platform for cranberry. The Flex-Seq genotyping technology offers repeatable, high-recovery, and high-density single nucleotide polymorphisms as well as concomitant haplotypes. The cranberry Flex-Seq platform contains 17,502 loci, boasting a recovery rate of 99.8% in a diversity panel of 192 cranberry accessions. The level of incompatible marker inheritance in 22 analyzed parent-offspring trios ranged from 1.1% to 13%, with an average of 5.5%. Nine of the 22 crosses had an excess of incompatible markers, indicating inconsistent parentage that could be investigated further. In quantitative trait loci (QTLs) analyses, Flex-Seq identified a greater number of QTLs compared to previously used GBS as well as higher overall logarithm of odds scores for overlapping QTLs. In addition, construction of locus haplotypes resulted in a substantial improvement in resolving the relatedness of cranberry accessions. This platform will aid in utilizing the untapped potential of wild cranberry, mapping key traits with higher precision, and ensuring robust characterization of accessions. The developed genotyping platform will help in the rapid improvement of cranberry cultivars to benefit breeders, growers, and consumers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.